JP2022540868A5 - - Google Patents
Info
- Publication number
- JP2022540868A5 JP2022540868A5 JP2022502030A JP2022502030A JP2022540868A5 JP 2022540868 A5 JP2022540868 A5 JP 2022540868A5 JP 2022502030 A JP2022502030 A JP 2022502030A JP 2022502030 A JP2022502030 A JP 2022502030A JP 2022540868 A5 JP2022540868 A5 JP 2022540868A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962873221P | 2019-07-12 | 2019-07-12 | |
| US62/873,221 | 2019-07-12 | ||
| PCT/CN2020/101727 WO2021008501A1 (en) | 2019-07-12 | 2020-07-13 | Engineered vaccinia virus |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022540868A JP2022540868A (ja) | 2022-09-20 |
| JPWO2021008501A5 JPWO2021008501A5 (https=) | 2024-09-27 |
| JP2022540868A5 true JP2022540868A5 (https=) | 2024-09-27 |
| JP7643739B2 JP7643739B2 (ja) | 2025-03-11 |
Family
ID=74102574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502030A Active JP7643739B2 (ja) | 2019-07-12 | 2020-07-13 | 遺伝子組換えワクシニアウイルス |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11739302B2 (https=) |
| EP (1) | EP3996743A4 (https=) |
| JP (1) | JP7643739B2 (https=) |
| CN (1) | CN114144196B (https=) |
| WO (1) | WO2021008501A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117004579B (zh) * | 2023-06-29 | 2024-11-15 | 苏州恩立维生物科技有限公司 | 重组溶瘤牛痘病毒及其应用 |
| WO2025157196A1 (zh) * | 2024-01-24 | 2025-07-31 | 深圳市华药康明生物药业有限责任公司 | 经修饰的痘苗病毒及其用途 |
| CN120349429B (zh) * | 2025-06-25 | 2025-08-22 | 武汉大学人民医院（湖北省人民医院） | 一种基于hic1功能结构域优化的重组蛋白及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7300774B1 (en) * | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
| MXPA04012116A (es) * | 2002-06-07 | 2005-04-19 | Zymogenetics Inc | Uso del il-21 en cancer y otras aplicaciones terapeuticas. |
| US20050163805A1 (en) * | 2002-10-01 | 2005-07-28 | O'neill Luke A.J. | Orthopoxvirus vectors, genes and products thereof |
| US20060275794A1 (en) * | 2005-03-07 | 2006-12-07 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
| WO2012040266A2 (en) * | 2010-09-24 | 2012-03-29 | University Of Miami | Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines |
| GB201405834D0 (en) * | 2014-04-01 | 2014-05-14 | Univ London Queen Mary | Oncolytic virus |
| EP3480307B1 (en) * | 2016-05-30 | 2021-06-23 | Astellas Pharma Inc. | New genetically-modified vaccinia virus |
| US10888594B2 (en) * | 2016-05-30 | 2021-01-12 | National University Corporation Tottori University | Genetically engineered vaccinia viruses |
| BR112021004692A2 (pt) * | 2018-09-15 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | poxvírus recombinantes para imunoterapia de câncer |
-
2020
- 2020-07-13 US US16/926,803 patent/US11739302B2/en active Active
- 2020-07-13 EP EP20841319.5A patent/EP3996743A4/en active Pending
- 2020-07-13 WO PCT/CN2020/101727 patent/WO2021008501A1/en not_active Ceased
- 2020-07-13 CN CN202080050466.6A patent/CN114144196B/zh active Active
- 2020-07-13 JP JP2022502030A patent/JP7643739B2/ja active Active
- 2020-07-13 US US17/626,288 patent/US20220257756A1/en not_active Abandoned